In contrast, Koh et al. reported that ERCC1 tumor immunoreactivity had no effect on chemotherapy response in patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CDDP containing induction chemotherapy [12]. The gene discussed is ERCC1; the disease is laryngeal carcinoma.